Literature DB >> 32666270

miR155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease.

Ben Readhead1,2, Jean-Vianney Haure-Mirande3, Joel T Dudley4, Michelle E Ehrlich5,6,7, Diego Mastroeni1, Mickael Audrain3, Tomas Fanutza3, Soong H Kim3, Robert D Blitzer8,9, Sam Gandy3,10,11,12.   

Abstract

MicroRNAs are recognized as important regulators of many facets of physiological brain function while also being implicated in the pathogenesis of several neurological disorders. Dysregulation of miR155 is widely reported across a variety of neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, and traumatic brain injury. In previous work, we observed that experimentally validated miR155 gene targets were consistently enriched among genes identified as differentially expressed across multiple brain tissue and disease contexts. In particular, we found that human herpesvirus-6A (HHV-6A) suppressed miR155, recapitulating reports of miR155 inhibition by HHV-6A in infected T-cells, thyrocytes, and natural killer cells. In earlier studies, we also reported the effects of constitutive deletion of miR155 on accelerating the accumulation of Aβ deposits in 4-month-old APP/PSEN1 mice. Herein, we complete the cumulative characterization of transcriptomic, electrophysiological, neuropathological, and learning behavior profiles from 4-, 8- and 10-month-old WT and APP/PSEN1 mice in the absence or presence of miR155. We also integrated human post-mortem brain RNA-sequences from four independent AD consortium studies, together comprising 928 samples collected from six brain regions. We report that gene expression perturbations associated with miR155 deletion in mouse cortex are in aggregate observed to be concordant with AD-associated changes across these independent human late-onset AD (LOAD) data sets, supporting the relevance of our findings to human disease. LOAD has recently been formulated as the clinicopathological manifestation of a multiplex of genetic underpinnings and pathophysiological mechanisms. Our accumulated data are consistent with such a formulation, indicating that miR155 may be uniquely positioned at the intersection of at least four components of this LOAD "multiplex": (1) innate immune response pathways; (2) viral response gene networks; (3) synaptic pathology; and (4) proamyloidogenic pathways involving the amyloid β peptide (Aβ).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32666270      PMCID: PMC8414561          DOI: 10.1007/s00401-020-02185-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  81 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Overview and findings from the religious orders study.

Authors:  David A Bennett; Julie A Schneider; Zoe Arvanitakis; Robert S Wilson
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

3.  Detection and monitoring of microRNA expression in developing mouse brain and fixed brain cryosections.

Authors:  Davide De Pietri Tonelli; Yoanne M Clovis; Wieland B Huttner
Journal:  Methods Mol Biol       Date:  2014

4.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

5.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

6.  Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology.

Authors:  Annerieke Sierksma; Ashley Lu; Evgenia Salta; Elke Vanden Eynden; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; David Blum; Luc Buée; Mark Fiers; Bart De Strooper
Journal:  Mol Neurodegener       Date:  2018-10-12       Impact factor: 14.195

7.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote.

Authors:  Yang Liao; Gordon K Smyth; Wei Shi
Journal:  Nucleic Acids Res       Date:  2013-04-04       Impact factor: 16.971

8.  APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses.

Authors:  Tomas Fanutza; Dolores Del Prete; Michael J Ford; Pablo E Castillo; Luciano D'Adamio
Journal:  Elife       Date:  2015-11-09       Impact factor: 8.140

9.  microRNAs in Neurodegeneration: Current Findings and Potential Impacts.

Authors:  Salil Sharma; Hui-Chen Lu
Journal:  J Alzheimers Dis Parkinsonism       Date:  2018-01-23

10.  Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients.

Authors:  Elisa Caggiu; Kai Paulus; Giuseppe Mameli; Giannina Arru; Gian Pietro Sechi; Leonardo A Sechi
Journal:  eNeurologicalSci       Date:  2018-09-14
View more
  5 in total

Review 1.  MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.

Authors:  T P Nhung Nguyen; Mandeep Kumar; Ernesto Fedele; Giambattista Bonanno; Tiziana Bonifacino
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

Review 2.  The Role of Human Herpesvirus 6 Infection in Alzheimer's Disease Pathogenicity-A Theoretical Mosaic.

Authors:  Constantin Romanescu; Thomas Gabriel Schreiner; Ilya Mukovozov
Journal:  J Clin Med       Date:  2022-05-29       Impact factor: 4.964

3.  Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25.

Authors:  Qiuyang Zheng; Guilin Li; Shihua Wang; Ying Zhou; Ke Liu; Yue Gao; Yulin Zhou; Liangkai Zheng; Lin Zhu; Qingfang Deng; Meiling Wu; Anjie Di; Lishan Zhang; Yingjun Zhao; Hongfeng Zhang; Hao Sun; Chen Dong; Huaxi Xu; Xin Wang
Journal:  Sci Adv       Date:  2021-01-01       Impact factor: 14.136

4.  USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and Aβ generation.

Authors:  Qiuyang Zheng; Beibei Song; Guilin Li; Fang Cai; Meiling Wu; Yingjun Zhao; LuLin Jiang; Tiantian Guo; Mingyu Shen; Huan Hou; Ying Zhou; Yini Zhao; Anjie Di; Lishan Zhang; Fanwei Zeng; Xiu-Fang Zhang; Hong Luo; Xian Zhang; Hongfeng Zhang; Zhiping Zeng; Timothy Y Huang; Chen Dong; Hong Qing; Yun Zhang; Qing Zhang; Xu Wang; Yili Wu; Huaxi Xu; Weihong Song; Xin Wang
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

Review 5.  Microglial TYROBP/DAP12 in Alzheimer's disease: Transduction of physiological and pathological signals across TREM2.

Authors:  Jean-Vianney Haure-Mirande; Mickael Audrain; Michelle E Ehrlich; Sam Gandy
Journal:  Mol Neurodegener       Date:  2022-08-24       Impact factor: 18.879

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.